BGXX Key Statistics, Chart & Performance
The current stock price of BGXX is 0.1481 USD. In the past month the price decreased by -38.75%. In the past year, price decreased by -56.11%.
BGXX Latest News, Press Relases and Analysis
BGXX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.13 | 959.08B | ||
| JNJ | JOHNSON & JOHNSON | 19.51 | 487.84B | ||
| MRK | MERCK & CO. INC. | 11.45 | 250.41B | ||
| PFE | PFIZER INC | 8.03 | 146.12B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.92 | 105.76B | ||
| ZTS | ZOETIS INC | 18.99 | 53.06B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.60B | ||
| VTRS | VIATRIS INC | 4.62 | 12.39B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.91 | 10.93B | ||
| CORT | CORCEPT THERAPEUTICS INC | 96.2 | 8.91B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.46B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.28B |
Related stock screener links
About BGXX
Company Profile
Bright Green Corp. engages in the cultivation, manufacture, and sale of medical cannabis. The company is headquartered in Fort Lauderdale, Florida and currently employs 5 full-time employees. The company went IPO on 2022-05-17. The firm specializes in the research, production, distribution, and advancement of plant-based drugs and APIs, including psilocybin, psilocyn, peyote, and opium poppy. The company plans to focus on the development of cannabis strains and sales of cannabis and hemp products with high contents of cannabinol (CBN) and cannabigerol (CBG). The company also plans to cultivate cannabis and focus on the production of dried flowers, and oils and marijuana extracts. In addition to cannabis, it also has a separate area for controlled substance cactus cultivation, and a separate controlled area for mushroom propagation. The company is in the process of completing construction of the 22-acre existing greenhouse to comply with the requirements for Schedule I and Schedule II plant-based drugs. The company also plans to construct two new 57-acre greenhouses, one each on the Candelaria property and Azuz property.
Company Info
BRIGHT GREEN CORP
401 East Las Olas Blvd., Suite 1400
Fort Lauderdale FLORIDA US
Employees: 5
Phone: 12013701140
BRIGHT GREEN CORP / BGXX FAQ
Can you describe the business of BRIGHT GREEN CORP?
Bright Green Corp. engages in the cultivation, manufacture, and sale of medical cannabis. The company is headquartered in Fort Lauderdale, Florida and currently employs 5 full-time employees. The company went IPO on 2022-05-17. The firm specializes in the research, production, distribution, and advancement of plant-based drugs and APIs, including psilocybin, psilocyn, peyote, and opium poppy. The company plans to focus on the development of cannabis strains and sales of cannabis and hemp products with high contents of cannabinol (CBN) and cannabigerol (CBG). The company also plans to cultivate cannabis and focus on the production of dried flowers, and oils and marijuana extracts. In addition to cannabis, it also has a separate area for controlled substance cactus cultivation, and a separate controlled area for mushroom propagation. The company is in the process of completing construction of the 22-acre existing greenhouse to comply with the requirements for Schedule I and Schedule II plant-based drugs. The company also plans to construct two new 57-acre greenhouses, one each on the Candelaria property and Azuz property.
What is the stock price of BRIGHT GREEN CORP today?
The current stock price of BGXX is 0.1481 USD. The price decreased by -22.01% in the last trading session.
What is the dividend status of BRIGHT GREEN CORP?
BGXX does not pay a dividend.
How is the ChartMill rating for BRIGHT GREEN CORP?
BGXX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is BRIGHT GREEN CORP (BGXX) stock traded?
BGXX stock is listed on the Nasdaq exchange.
What sector and industry does BRIGHT GREEN CORP belong to?
BRIGHT GREEN CORP (BGXX) operates in the Health Care sector and the Pharmaceuticals industry.
BGXX Technical Analysis
BGXX Financial Highlights
Over the last trailing twelve months BGXX reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS increased by 40.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.04% | ||
| ROE | -100.53% | ||
| Debt/Equity | 0.05 |